Concerning other biologics agents, active tuberculosis was not reported in a cohort of 12000 patient with psoriasis and spondyloarthritis treated with Secukinumab.25 Moreover, there were no instances of active TB development under jak-inhibitors compared to TNF inhibitors in a prospective Korean cohort.26 Only 1% of our registry was treated with Secukinumab; therefore, the data was insufficient to draw strong conclusions. Here, TNF is linked to spondyloarthropathy.